"A new consumer-friendly form ( is now available for making
reports to MedWatch, the Food and Drug Administration's (FDA)
on-line system for collecting information about serious problems
with drugs, medical devices and other FDA-"... Hemophilia A is a
hereditary bleeding disorder characterized by deficient
coagulant activity of the specific plasma protein clotting
factor, factor VIII. In afflicted individuals, hemorrhages may
occur spontaneously or after only minor trauma. Surgery on such
individuals is not feasible without first correcting the
clotting abnormality. The administration of Koate
(antihemophilic factor) -DVI provides an increase in plasma
levels of factor VIII and can temporarily correct the
coagulation defect in these patients. After infusion of
Antihemophilic Factor (Human), there is usually an instantaneous
rise in the coagulant level followed by an initial rapid
decrease in activity, and then a subsequent much slower rate of
decrease in activity.2-4 The early rapid phase may represent the
ti